Arvinas Inc

Arvinas insider sales on May 11, 2026 were tax‑driven and not a sign of declining confidence, even as a new Rigel/Pfizer licensing deal could boost profitability.

Arvinas insider buying shows executive confidence, while tax‑related CMO sales don’t dampen optimism—Phase 1 Parkinson data boosts the stock’s upside potential.

Arvinas insider sales reveal routine tax‑settlement, not strategic divestiture—insiders hold strong confidence while the company advances its PROTAC pipeline.